^
    Back
    Association details:
    Biomarker:IDH2 mutation
    Cancer:Glioblastoma
    Drug:bintrafusp alfa (M7824) (PD-L1 inhibitor, TGFβ inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Neurooncol Adv
    Title:

    Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-ß and PD-L1: results from a phase I expansion cohort in patients with recurrent glioblastoma

    Published date:
    04/09/2021
    Excerpt:
    ...patients with rGBM that progressed after radiotherapy plus temozolomide received bintrafusp alfa 1200 mg Q2W until disease progression....The DCR (95% CI) was 66.7% (22.3-95.7%) for patients with IDH-mutant GBM (n = 6) and 13.8% (3.9-31.7%) for patients with IDH-wild-type GBM (n = 29).
    DOI:
    10.1093/noajnl/vdab058
    Trial ID:
    EMR 200647-001